Abstract: Objective To observe the efficacy of pegylated interferon α-2a combined with adefovir dipivoxil and their effects on serum T lymphocyte cytokines and hepatic fibrosis indexes in patients with HBeAg-positive chronic hepatitis B（CHB）. Methods 144 patients with CHB were randomly divided into observation group and control group with 72 cases in each group according to the inclusion orders. The patients in control group was given adefovir dipivoxil, and in the observation group was given pegylated interferon α-2a combined with adefovir dipivoxil. After 24-week treatment,the efficacy of treatment,and changes of serum IL-2,IL-10,IL-6 and INF-γ and PⅢP,LN,HA and Ⅳ-C in each group were recorded. Results At the end of 24 weeks of treatment,the negative rates of serum HBV DNA,HBeAg and HBeAg/anti-HBe seroconversion in observation group were 72.22%,58.33% and 41.67%,respectively,much higher than those in the control group（5.56%,22.22% and 20.83%,respectively,P<0.05 for all）;Compared with in control group,serum IL-2 and INF-γ in observation group were much higher [（2.18±1.26） pg/ml vs. （1.71±1.05） pg/ml,and （99.65±11.03） pg/ml vs. （85.70±11.82） pg/ml,P<0.05 for both],while serum IL-6 and IL-10 levels were much lower [（4.53±2.15） pg/ml vs. （5.47±2.25） pg/ml,and （15.42±9.39） pg/ml vs.（20.07±13.08） pg/ml,P<0.05 for both];Serum hepatic fibrosis indexes in observation group were much lower than those in the control group [HA （127.28±59.60） μg/L vs. （261.35±81.46） μg/L,LN （110.52±37.39） μg/L vs. （162.32±38.82） μg/L,Ⅳ-C （116.56±28.61） μg/L vs. （174.13±43.05） μg/L, PⅢ（163.65±64.38） μg/L vs. （212.43±64.25） μg/L,P<0.05 for all]. Conclusion Compared with single use of adefovir dipivoxil,pegylated interferon α-2a combined with adefovir dipivoxil have better antiviral effects and better improvement on T lymphocyte cytokines and hepatic fibrosis indexes in patients with HBeAg-positive chronic hepatitis B.

Key words: Chronic hepatitis B, Pegylated interferon α-2a, Adefovir dipivoxil, Cytokines, Hepatic fibrosis index